14 ANNUAL TH

October 20-21, 2015 San Francisco

Advisory Committee Why Attend BIO Investor Forum?

John Chambers

INDEPENDENT HOST — One of the only independent investor conferences dedicated to helping early-stage biotech companies find sources of capital. EFFICIENT PARTNERING — Ideal venue for investors and company executives to discuss financial and strategic business issues affecting investment in biotech companies and explore potential partnerships and business collaborations to fuel research and development for promising innovation. GLOBAL SCOPE — Attracts healthcare venture capital and public market investors and research analysts as well as business development executives from leading global pharmaceutical and biotechnology companies. COMPELLING VOICES — Offers ample networking opportunities, informative therapeutic and business workshops, and presentations from up-and-coming companies.

New in 2015 The BIO SPARK Showcase Event provides an excellent opportunity for academic researchers in the SPARK network to showcase drug development programs that are ready for partnering or venture funding. The symposium will feature a keynote speech by Dr. Daria Mochly-Rosen, SPARK Director and George D. Smith Professor in Translational Medicine, Stanford University School of Medicine. BIO and FierceBiotech will celebrate the 15 privately held drug developers and platform biotechs with the potential to have a huge impact on the treatment of human diseases.

-1-

Vice-Chairman and Head of Healthcare Investment Banking, ROTH Capital Partners

Jason Hafler Director of Investments, Sanofi-Genzyme BioVentures

Charlotte Hubbert Program Investment Officer, Program Related Investments, Bill and Melinda Gates Foundation

Jennifer Landress, CMP

AT STANFORD

Vice President, TPG Biotech

Vikas Goyal, MBA Principal, S.R. One, Limited

Paulina Hill Principal, Polaris Partners

Stephen T. Isaacs

Senior Vice President and Chief Operating Officer, Biocom

President and CEO, Aduro Biotech

Julie Papanek

Arlene Morris

Principal, Canaan Partners

S PA R K

Cayce Denton

John Poulos Vice President, Head of Licensing and Acquisitions, AbbVie

Sara Radcliffe President & CEO, California Life Sciences Association (CLSA)

CEO, Willow Advisors

Jit Patel Vice President of Research Business Development, JDRF

David Woodhouse Chief Financial Officer, NGM Biopharmaceuticals

Asish K. Xavier, PhD Vice President, Venture Investments, J&J Development Corporation

-2-

Therapeutic Panel Topics

Therapeutic Panel Topics

Report from the Frontier: Emerging Oncology Trends Bridging ASCO to ASH

Stretching Your Dollar: Methods and Tools for Increasing the Productivity of Clinical Trials

Tuesday, October 20, 10:30 a.m. - 11:25 a.m.| 4th Floor, Mission Room If you missed the most important oncology event so far this year, this panel will address the key takeaways and what’s new since then. Just how important is PD-1 in your portfolio? CAR-T: is it still the game changing technology since 2014? What role will combination therapies play going forward into 2016? Will dendritic cell therapies maintain relevance in the immuno-oncology space? What does the ideal immuno-oncology portfolio look like? Will we continue to see partnering of assets amongst emerging biotechs?

Moderator: • Jeff Smith, PhD, Vice President, Investment Banking, H.C. Wainwright & Co.

Panelists: • Louis J. DeGennaro, PhD, President & CEO, The Leukemia & Lymphoma Society (LLS) • Olivier Lesueur, Managing Director, BIONEST Partners • Ben Thorner, VP Business Development & Licensing, Head of North American Innovation Hubs, Merck Research Laboratories • Geeta Vemuri, PhD, Managing Partner, Baxalta Ventures • Jeffrey Wolf, Founder & CEO Heat Biologics

Precision Medicine: Leveraging National Genomic Databases for Therapy Development (U.S., UK, Iceland) Tuesday, October 20, 9:00 a.m. - 9:55 a.m.| 4th Floor, Mission Room As the price point for full genome analysis falls through the $1,000 per person milestone, national efforts are ramping up for large studies that should enable much more personalized therapies. This data should accelerate drug development by clarifying genetic targets and the most appropriate patient sub-groups for clinical trials. The US’s NIH is planning a million-person database, the UK’s NHS is already recruiting a 100,000 genome collection, and Iceland’s deCODE initiative has already produced findings from its 160,000 person database. This panel will discuss the variety of strategies drug/therapy developers can apply to leverage these infrastructure investments most effectively.

Panelists: • Esteban G. Burchard, MD, MPH, Professor of Medicine and Bioengineering and Therapeutic Sciences, University of California, San Francisco (invited) • Neil Campbell, President and Chief Executive Officer, Helomics • Andrew May, D.Phil., Chief Scientific Officer, Caribou Biosciences • Matthew Scholz, CEO, Immusoft • Pamela Sklar, MD, PhD, Chief, Division of Psychiatric Genomics, Icahn School of Medicine at Mount Sinai  • Hannes Thor Smárason, Co-Founder and COO, WuXi NextCODE

-3-

Wednesday, October 21, 10:30 a.m. - 11:25 a.m.| 4th Floor, Mission Room Recent Tufts data show clinical trials typically take nearly twice as long to complete enrollment as predicted at launch and 48% of trial sites miss enrollment targets. Delays in trials shrink the returns from patent exclusivity and increase R&D costs. New methods such as adaptive and batch trial designs, as well as explosive growth in digital tools, such as Apple’s ResearchKit, have transformed the trial design choices available. These innovations, and others, provide new levers for boosting productivity of clinical trials—with positive implications for improving cash burn rates and accelerating speed-to-market.

Moderator: • Sastry Chilukuri, Partner, McKinsey & Company

Panelists: • Noah Craft MD, PhD, DTM&H, Co-Founder & CEO, Science 37, Inc. • Michael V. McConnell, MD, MSEE, Professor of Medicine, Director of Cardiovascular Health Innovation and PI of the MyHeart Counts mHealth research study, Stanford School of Medicine • Matt Noble, Senior Director, Product Management, Medidata Solutions • Komathi Stem, Strategic Innovation Leader, Genentech (invited)

Policy Outlook—Valuation Model Implications of 21st Century Cures, IP Reform, TPP, and PDUFA VI Tuesday, October 20, 2:00 p.m. - 2:55 p.m.| 4th Floor, Mission Room 2015 is producing more legislative and regulatory policy changes that apply to drug development than the industry has seen in several years. Each shift in exclusivity rules, patient-centered endpoints, patent challenge rules, or FDA application policies can dramatically affect how you—and your investors—value your therapeutic pipeline. Join this panel moderated by a BIO policy expert on whether some or all these proposals will actually take effect.

Moderator: • Cartier Esham, PhD, Executive Vice President, Emerging Companies, BIO

Panelists: • Paul J. Hastings, Chairman & CEO, OncoMed Pharmaceuticals • Elizabeth Krutoholow, Analyst, Bloomberg Intelligence • Andrew N. Merickel, PhD, Partner, Knobbe Martens • Sara Radcliffe, MPH, President & CEO, California Life Sciences Association

(Speakers added daily. Please visit www.bio.org/investorforum for most up to date program and confirmed presenters).

-4-

Business Panel Topics

Business Panel Topics

Investor Management Lessons of Fierce 15 Alumni CEOs

BioCentury Presents: Courting Crossover Investors

Tuesday, October 20, 4:30 p.m. - 5:25 p.m.| 4th Floor, Mission Room

Wednesday, October 21, 2:00 p.m. - 2:55 p.m. | 4th Floor, Mission Room

Each year FierceBiotech’s John Carroll has identified the “fiercest” private companies most likely to create dramatic growth for their investors. As many of those private companies went public, those CEOs’ relationships with their Boards evolved as pure venture investors made their exits. What are the most important factors investors look for in company management teams—and vice versa? How closely does the board align with company management to make an attractive investment offering? And what makes the investment banks see real value when looking at a potential IPO? Join past Fierce 15 winners as they discuss what they have learned.

The participation rate of crossover investors in biotech venture funding rounds has been growing at more than 50% per year since 2012 with anecdotal information suggesting a near necessity of such involvement to maximize a company’s IPO performance. BioCentury will provide new data to quantify the impact of crossover fund involvement as well as foster a panel discussion of the “do’s and don’ts” of managing relationships with such investors.

Moderator:

Panelists:

• John D. Carroll, Editor-in-Chief, FierceBiotech

Panelists: • Thomas E. Hughes, PhD, Zafgen (invited) • Stephen T. Isaacs, Chairman, President, and CEO, Aduro Biotech

Venture Capital Funding Trends: BIO Analysis of Ten Years of Investment and the Gaps that Appear

• Steve Edelson, Senior Editor, Finance, BioCentury Publications, Inc. • James Healy, MD, PhD, General Partner, Sofinnova Ventures • Nathan Hubbard, Vice President Transactions, Oncology and Diagnostics, Eli Lilly and Company • Oleg Nodelman, Founder and Managing Director, EcoR1 Capital • Jonathan Norris, Managing Director, Silicon Valley Bank • Dinesh V. Patel, PhD, President & CEO, Protagonist Therapeutics

Wednesday, October 21, 9:00 a.m. - 9:55 a.m.| 4th Floor, Mission Room

Market Outlook—Status of the IPO Appetite, M&A, Foreign Shocks, and Higher Interest Rates?

BIO’s recent analysis of investment and deal trends across the past decade for emerging therapeutic companies found three remarkable gaps between where VCs have placed their investments and what might be expected by biotech CEOs. First, despite a remarkable growth in the number of start-ups, there appears to be a bottleneck of about 65 Series A rounds made per year—why? Second, the period sees a shift in popularity away from common chronic diseases toward rare diseases and oncology—how permanent is this therapeutic bias? Third, crossover investors are supporting more private companies earlier, but the total amount of Series A funding per year appears much flatter than the rocketing total of IPO value creation—will that venture money come back or are good startups getting frozen out? Learn from the investors making the individual decisions and how they see these trends continuing or changing in the future.

Wednesday, October 21, 4:30 p.m. – 5:30 p.m.| 4th Floor, Mission Room While the appetite for new IPOs remains strong and cash is still flowing freely in the capital intensive biotech sector, concerns over valuation have the public markets on high alert. Investment banks are competing for the next biggest IPO with less clinical evidence in place up front. As M&A among payers and among biopharmas start a new round of consolidation, what does all this mean for privately held companies? Global economic factors have had a serious impact across all sectors, but how will biotech be affected? Has the biotech sector’s resilience strengthened since the last downturn? This panel of diverse experts will discuss what we can learn from history and where the market is crossing a new frontier.

Moderator:

Panelists:

• Michael J. O’Donnell, Partner, Morrison & Foerster

Panelists: • Lindy Fishburne, Executive Director, Breakout Labs; SVP for Investments, Thiel Foundation • Charlotte Hubbert, Program Investment Officer, Venture Investing, The Bill & Melinda Gates Foundation • Camille Samuels, Partner, Venrock • David Thomas, CFA, Senior Director, Industry Research and Policy Analysis, BIO • Ilan Zipkin, PhD, Senior Investment Director, Takeda Ventures

-5-

Moderator:

• John Chambers, Vice-Chairman and Head of Healthcare Investment Banking, ROTH Capital • Margarita Chavez, Director, Venture & Early Stage Collaborations, AbbVie Biotech Ventures • Asthika Goonewardene, Senior Biotech Analyst, Bloomberg Intelligence • David Woodhouse, PhD, Chief Financial Officer, NGM Biopharmaceuticals

-6-

Fireside Chats at Plenary Luncheons

NEW!

BIO is pleased to feature Robert Nelsen and James Noble as this year’s fireside chat speakers! Fireside chats feature candid discussions between biopharma senior executives and industry experts. Hear about recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2016. James Noble Adaptimmune CEO

Robert T. Nelsen ARCH Venure Partners

Moderated by: Tony Gibney, Managing Director, Leerink Partners LLC

Co-Founder and Managing Director Moderated by: Matthew Rossiter, Partner, Fenwick & West

Tuesday, October 20, 12:30-1:25 p.m.

Wednesday, October 21, 12:30-1:25 p.m

Participating Investors* Below is the preliminary list of 2015 participating investors for the BIO Investor Forum. 5AM Ventures Alpha Bronze Aquilo Capital Astellas Venture Management ATEL Ventures ATEM Capital Avalon Ventures Baxter Ventures Bay City Capital Bill & Melinda Gates Foundation BioEngine Technology Development BioInnovation Capital Biomark Capital Brace Pharma Capital Bridge Bank BVF Partners Canaan Partners Chardan Capital Markets China Health Industry Capital Investment China Healthcare Industrial Capital Fund Management (Shanghai) Co., Ltd Claremont Creek Ventures Claremont Creek Ventures Codon Capital CRG LP Diamond BioFund Inc. EcoR1 Capital Finance Technology Leverage

-7-

Frazier Healthcare Partners GE Capital, Life Sciences GE Ventures Hercules Technology Growth Capital Inventis Investment Holdings (China) J.P. Morgan Juvenile Diabetes Research Foundation International JMP Securities Johnson & Johnson Innovation - JJDC Jump Capital Kearny Venture Partners Life Science Angels Lincoln Park Capital Longitude Capital Lumira Capital MBL Venture Capital Co., Ltd Medimmune Ventures, Inc Mill Valley Partners MIT Angels Mitsui & Co. Global Investment Moore Venture Partners NanoDimesion New Leaf Venture Partners Novo Ventures Oberland Capital Oppenheimer & Co., Inc. OrbiMed Advisors

Oxford Finance LLC Palo Alto Investors PharmaFund LLP Platform Houston Precision Bioventures Sacramento Angels and Chemical Angels Network Sanderling Ventures Solar Capital SR One SunTrust Robinson Humphrey, Inc. Synthesis Capital Tavistock Tech Coast Angels The Angels’ Forum The University of California VantagePoint Capital Partners Venrock Versant Ventures Vertex Venture Holdings Vivo Capital WRF Capital



*As of 9/28/2015

Presenting Companies The following is the list of presenting companies for the 14th Annual BIO Investor Forum. Presenters will consist of Discovery Companies (under 25M raised to date in Seed or Series A financing rounds), established private companies (over 25M raised and in Series B and above) and emerging public companies. CARDIOVASCULAR

Euclises Pharmaceuticals, Inc. Felicitex Therapeutics GenSpera, Inc. (OTCQB: GNSZ) Geron Corporation (NASDAQ: GERN) Helix Biopharma Corp. (TSX: HBP) CNS/NEUROLOGICAL Helomics Corporation AgeneBio ImmunGene, Inc. Agilis Biotherapeutics Immunovaccine Inc. (TSX; OTCQX: Amarantus BioScience Holdings, Inc. IMV; IMMVF) (OTCQX: AMBS) INFLAMMATION MEI Pharma, Inc. (NASDAQ: MEIP) Cerecor Inc. (NASDAQ: CERC) AbGenomics International Inc. Meryx Inc. Comentis Complexa Monopar Therapeutics Embera NeuroTherapeutics, Inc. Corbus Pharmaceuticals Holdings, Inc. Navidea Biopharmaceuticals (NYSE Impel NeuroPharma (NASDAQ: CRBP) MKT: NAVB) Ixchel Pharma LLC Relburn-Metabolomics, Inc. Neovia Oncology Ltd KineMed, Inc. Oncoceutics, Inc. MEDICAL DEVICES NeuroGenetic Pharmaceuticals Oncolytics (NASDAQ: ONCY) Bionik Laboratories Corp. (OTCBB: Probiodrug (Euronext: PBD) BNKL) OncoSec Medical, Inc. (NASDAQ: Trigemina, Inc. ONCS) MedLumics S.L. WinSanTor PCI Biotech (OSB: PCIB) Zynerba Pharmaceuticals (NASDAQ: METABOLIC DISEASES Rexahn Pharmaceuticals (NYSE MKT: Galmed Pharmaceuticals (NASDAQ: ZYNE) RNN) GLMD) DERMATOLOGY Sellas Life Sciences Group MAX BioPharma MiNDERA Corp. SolaranRx, Inc. Sensor Pharmaceuticals, Inc. RXi Pharmaceuticals Corporation Spectrum Pharmaceuticals Thetis Pharmaceuticals LLC (NASDAQ: RXII) (NASDAQGS: SPPI) Thrasos Therapeutics Inc. TransDerm Susavion Biosciences, Inc. Viking Therapeutics, Inc. (NASDAQ: DIAGNOSTICS Sutro Biopharma VKTX) Amadix The Leukemia & Lymphoma Society Xeris Pharmaceuticals, Inc. Biocept (NASDAQ: BIOC) Tokai Pharmaceuticals, Inc. (NASDAQ: Zafgen (NASDAQ: ZFGN) BioMarker Strategies TKAI) NON-PROFIT/ADVOCACY INanoBio Inc. Xcovery ORGANIZATION Mediomics, LLC OPHTHALMOLOGY The National MS Society/Fast Moleculera Labs ActiveSite Pharmaceuticals, Inc. Forward, LLC OncoCyte Corporation Isarna Therapeutics Trade Office of Ecuador in Los Provista Diagnostics, Inc. Makindus, Inc. Angeles DRUG DELIVERY Nicox SA (Euronext Paris: COX) ONCOLOGY Glide Technologies NovaBay Pharmaceuticals (NYSE: AbVitro Inc. Neos Therapeutics (NASDAQ: NEOS) AhR Pharmaceuticals, Inc. NBY) Portal Instruments Tyrogenex Aptose Biosciences Inc. (NASDAQ; GASTROINTESTINAL ORPHAN/RARE DISEASES TSX: APTO; APS) Avexegen Therapeutics Antegrin Therapeutics, Inc. ARMO BioSciences LiveLeaf BioScience Aten Porus Lifesciences Atossa Genetics Inc. (NASDAQ: Protagonist Therapeutics Inc. ATOS) Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) RDD Pharma Avelas Biosciences, Inc. DelMar Pharmaceuticals, Inc. (OTCQX: TaiwanJ Pharmaceuticals Batu Biologics DMPI) BioCurity Holdings, Inc. GENE/CELL THERAPY Fennec Pharmaceuticals (TSX; Bio-Path Holdings, Inc. (NASDAQ: Benitec Biopharma (ASX: BLT) OTCQB: FRX; FENCF) BPTH) MultiVir Inc. Global Blood Therapeutics (NASDAQ: BriaCell Therapeutics Corp. (OTCQB: Opexa Therapeutics (NASDAQ: GBT) ANCCF) OPXA) Laurent Pharmaceuticals Cantex Pharmaceuticals, Inc. IMMUNOLOGY Mast Therapeutics, Inc. (NYSE MKT: Capella Therapeutics, Inc. Anthera Pharmaceuticals, Inc. MSTX) Cellectar Biosciences (NASDAQ: (NASDAQ: ANTH) Newron Pharmaceuticals SpA (SIX: CLRB) Kineta, Inc. NWRN) Colby Pharmaceutical Company Oxis International, Inc. (OTC: OXIS) Ocera Therapeutics, Inc. (NASDAQ: Cold Genesys, Inc. RuiYi OCRX) Cormorant Pharmaceuticals INFECTIOUS DISEASES Savara Critical Outcome Technologies Inc. C3 Jian, Inc. Thrombotargets Europe (TSXV; OTCQB: COT; OTCQF) ContraFect (NASDAQCM: CFRX) True North Therapeutics, Inc. Curis, Inc. (NASDAQ: CRIS) EnGeneIC Ltd. Armetheon RECARDIO Inc. Resverlogix Corp. (TSX: RVX)

ContraVir Pharmaceuticals (NASDAQ: CTRV) Curza InvVax, Inc. Matinas BioPharma Holdings, Inc. (OTCQB: MTNB) Rebiotix Inc. TheraBiol, Inc. Valley Fever Solutions

OTHER Amunix Aurinia Pharmaceuticals (NASDAQ: AUPH) Kadmon Corporation Richcore Lifesciences Synthetic Biologics, Inc. (NYSE MKT: SYN) Whole Biome Inc.

PAIN MANAGEMENT

DURECT Corporation (NASDAQ: DRRX) Nuvo Research Inc. (TSX: NRI) Relmada Therapeutics (OTCQB: RLMD)

PLATFORM FOR THERAPEUTICS Cloud Pharmaceuticals Cyclica Inc. Encycle Therapeutics Pronutria Biosciences Resilience Therapeutics, Inc. Symic Biomedical Transparency Life Sciences, LLC

REGENERATIVE MEDICINE

Aegle Therapeutics Corporation ECBio Histogenics Corporation (NASDAQ: HSGX) Magnus Life Science Silver Creek Pharmaceuticals, Inc. ViaCyte

REPRODUCTIVE/SEXUAL HEALTH

Apricus Biosciences, Inc. (NASDAQ: APRI) Palatin Technologies, Inc. (NYSE MKT: PTN)

RESPIRATORY

Axikin Pharmaceuticals Inc. Biomay AG Cortex Pharmaceuticals, Inc. (NASDAQ; OTCQB: CORX) LA BioMed Pulmatrix (NASDAQ: PULM) Silurian Pharmaceuticals

TOOLS/DRUG DEVELOPMENT SUPPORT TECHNOLOGY Protein Dynamic Solutions LLC Twist Bioscience, Corp

VACCINES

Adjuvance Technologies Aurora BioPharma, Inc. Protein Sciences Proventus Bio



*As of 9/28/2015

-8-

One-on-One PartneringTM Meetings BIO One-on-One Partnering™ is the most efficient and economical way to develop new business relationships. This interactive environment allows you to increase your meeting productivity, discover new investment and licensing opportunities and expand your business partnerships worldwide. Using this online tool, you will be able to:

Pre-schedule 25-minute, private 1x1 meetings; Search company and investor profiles, drug assets, products and services in the biotech and pharmaceutical industries; Evaluate potential collaborations and funding opportunities with participating companies; and Communicate directly with prospective investors and senior management.

Audience Demographics Over 40% of attendees were C-level Executives

Attendee Profile BD/Licensing 15% Investors 34%

Biotech Execs 33%

For questions about the BIO One-on-One Partnering™ System, please contact [email protected].

Other 18%

Investor Profile

More than 1,400 One-on-One meetings scheduled at BIF through BIO One-on-One Partnering™ in 2014

Sell-Side Research: 8%

Venture Capitalist 60%

Buy-Side Research: 8%

2014 Meeting Directionality

Institutional Investor: 7%

Investors to Investors 2%

Other 8%

Portfolio Manager 9%

Company to Company 34%

Company to Investors 40%

-9-

Investors to Company 24%

400+ companies 200+ investors

“A fantastic way to meet with many3D potential investors 130/170/20/35 and business partners. This way, I easily saved on 8-10 separate business trips.”

3D 130/170/20/35

-10-

Registration

Sponsors Regional Co-Hosts

Supporting Bank Sponsors

BIO Double Helix Sponsors

BIO Helix Sponsors

BIO offers a number of ways for conference attendees to save money on their registration fees. Discounted rates apply to the following:

3 Biotech companies that have raised less than $25 million in capital. 3 Presenting companies bringing three or more attendees. 3 Companies bringing more than two employees.

Industry Supporter

3 Corporations or other entities that use biotechnology or related technologies for research and development of products or information.

3 Academic institutions.

Conference Supporters Executive & Board Search

Qualified institutional and venture investors are eligible for complimentary registration. Tiberend

Strategic Advisors, Inc.

Register today at bio.org/investorforum Media Partners

®

Hotel/Venue Information Parc 55 San Francisco, A Hilton Hotel 55 Cyril Magnin Street San Francisco, CA 94102 (415) 392-8000 Book your room today to also receive the discounted room rate. Reservation requests are based on availability, space is limited.

-11-

Contact us today for a tailored sponsorship package that will meet your business objectives. Contact Fabien Rabanal at [email protected] or call (202) 962-9278. For more information on BIO sponsorships, please visit www.bio.org/sponsor

Join the conversation:

Learn more about Biotechnology at bio.org Engage with the Biotech Community at BIOtech-NOW.org Follow us on Twitter @bio1x1 Become a fan on Facebook (facebook.com/IAmBiotech)